DreamCIS, Inc. (KOSDAQ:223250)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,100.00
+60.00 (1.19%)
At close: Apr 28, 2026
70.00%
Market Cap 125.46B
Revenue (ttm) 66.63B
Net Income (ttm) 7.13B
Shares Out 24.60M
EPS (ttm) 298.00
PE Ratio 17.11
Forward PE 11.62
Dividend n/a
Ex-Dividend Date n/a
Volume 187,247
Average Volume 76,023
Open 5,040.00
Previous Close 5,040.00
Day's Range 4,950.00 - 5,340.00
52-Week Range 2,865.00 - 8,070.00
Beta 0.49
RSI 54.31
Earnings Date May 11, 2026

About DreamCIS

DreamCIS, Inc. operates as a clinical research organization in South Korea. It offers clinical development services; biostatics, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services. The company was founded in 2000 and is headquartered in Seoul, South Korea. DreamCIS, Inc. operates as a subsidiary of Hangzhou Tigermed Consulting Co., Ltd. [Read more]

Industry Commercial Physical and Biological Research
Founded 2000
Employees 390
Stock Exchange KOSDAQ
Ticker Symbol 223250
Full Company Profile

Financial Performance

In 2025, DreamCIS's revenue was 66.63 billion, an increase of 13.60% compared to the previous year's 58.65 billion. Earnings were 7.13 billion, an increase of 34.97%.

Financial Statements

News

There is no news available yet.